在小鼠疟疾模型中，使用重组腺病毒疫苗进行异源初免-加强免疫方案时增强的CD8 T细胞免疫原性和保护效力。

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

作者信息

Gilbert Sarah C, Schneider Jörg, Hannan Carolyn M, Hu Jiang Ting, Plebanski Magdalena, Sinden Robert, Hill Adrian V S

机构信息

Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK.

出版信息

Vaccine. 2002 Jan 15;20(7-8):1039-45. doi: 10.1016/s0264-410x(01)00450-9.

DOI:10.1016/s0264-410x(01)00450-9

PMID:11803063

Abstract

Recombinant replication-defective adenovirus expressing the CS gene from Plasmodium berghei (Ad-PbCS) was found to induce a strong CD8(+) T cell response after intra-dermal or -muscular immunisation. Boosting of an adenovirus-primed immune response with the replication-impaired poxvirus, modified vaccinia virus Ankara (MVA) led to enhanced immunogenicity and substantial protective efficacy. The recombinant adenoviral vaccine was capable of boosting to protective levels a CD8(+) T cell response primed by either a plasmid DNA vaccine, a recombinant Ty virus-like particle vaccine or recombinant MVA each expressing the same epitope or antigen. Complete protective efficacy after intradermal immunisation was observed with the adenovirus prime-MVA boost regime. This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses.

摘要

表达伯氏疟原虫CS基因的重组复制缺陷型腺病毒（Ad-PbCS）经皮内或肌肉免疫后能诱导强烈的CD8(+) T细胞应答。用复制受损的痘病毒——安卡拉改良痘苗病毒（MVA）加强腺病毒引发的免疫应答，可增强免疫原性并产生显著的保护效力。该重组腺病毒疫苗能够将由分别表达相同表位或抗原的质粒DNA疫苗、重组Ty病毒样颗粒疫苗或重组MVA引发的CD8(+) T细胞应答加强至保护水平。腺病毒初免-MVA加强方案在皮内免疫后观察到了完全的保护效力。本研究确定重组复制缺陷型腺病毒可作为重组复制缺陷型痘病毒的替代物，作为加强剂用于诱导强烈的保护性CD8(+) T细胞应答。